🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Beam Therapeutics CFO sells shares worth over $174k

Published 04/03/2024, 07:41 PM

Beam Therapeutics Inc. (NASDAQ:BEAM) has reported a significant transaction involving its Chief Financial Officer, Terry-Ann Burrell. According to the latest SEC filing, Burrell sold 5,446 shares of the company's common stock on April 1, 2024, for a total value exceeding $174,925.

The shares were sold at a weighted average price of $32.12, with individual transactions occurring within a price range of $32.10 to $32.18. This sale was conducted automatically under a Rule 10b5-1 trading plan, which Burrell had previously established on May 19, 2023. The plan is designed to allow insiders to sell their shares at predetermined times and prices, thus preventing any accusations of trading on non-public, material information.

The transaction was executed to cover tax withholding obligations related to the vesting of certain restricted stock units granted to Burrell under Beam Therapeutics' 2019 Equity Incentive Plan. These units vested on March 31 of the years 2021, 2022, and 2023.

Following this sale, Terry-Ann Burrell still holds a substantial number of shares in Beam Therapeutics, with a total of 70,137 shares remaining in her possession. The company, which specializes in biological products and operates out of Cambridge, Massachusetts, has not made any additional comments regarding this transaction.

Investors and followers of Beam Therapeutics will be keeping a close eye on the company's stock performance and any further insider trading activity to gauge the confidence level of its executives and their outlook on the company's future.

InvestingPro Insights

Beam Therapeutics Inc. (NASDAQ:BEAM) has been the subject of investor attention following a notable insider transaction by its CFO. The company's financial metrics provide a broader context for understanding its market position. With an adjusted market capitalization of $2.34 billion, Beam's scale in the biotech industry is noteworthy. Despite the company's negative earnings figures, with a P/E ratio of -17.34 and an adjusted P/E ratio for the last twelve months as of Q4 2023 at -19.25, investors are likely considering the company's growth potential and future profitability.

The company's revenue growth has been extraordinary, with a 520.01% increase over the last twelve months as of Q4 2023, and a staggering quarterly revenue growth of 1478.04% in Q4 2023. This explosive growth rate may be a key factor for investors assessing the company's long-term value. However, it's important to note the negative gross profit margin of -15.8%, indicating that Beam is currently spending more to produce its goods than it earns from sales.

InvestingPro Tips highlight that Beam's recent price performance shows a mixed picture, with a 1-week total price return of -12.6% but a 6-month total price return of 32.56%, suggesting volatility but also potential recent gains for longer-term investors. Additionally, the current price is at 59.96% of its 52-week high, which may indicate a potential upside if the company's growth trends continue.

For investors looking for more in-depth analysis, InvestingPro offers additional insights. There are currently 25+ InvestingPro Tips available, which can help investors make more informed decisions. To access these tips and gain a comprehensive understanding of Beam Therapeutics' financial health and prospects, consider subscribing to InvestingPro. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.